Kunming Pharmaceutical Group said it expected a net loss attributable to shareholders for the first half of 2026.
According to Jin10, the company announced it expected net profit attributable to shareholders to be between -400 million yuan and -330 million yuan, compared with net profit of 198 million yuan in the same period a year earlier, representing a year-on-year decline of 302% to 266%.
The company said the expected loss was mainly due to external factors including an expanded scope of centralized procurement for traditional Chinese patent medicines, deeper medical insurance cost controls, and intensified competition in non-hospital channels. It also cited internal adjustments such as optimizing channel inventory and advancing a shift in its marketing model, adding that progress in improving operations fell short of expectations.
STOCKS | Kunming Pharmaceutical Group Expects First-Half Net Profit to Swing to Loss
2026-07-14 09:31:33
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
明尼苏达州82岁男子遭冒充银行和联邦调查局诈骗
